»ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Çü, Á¦Ç°, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, ÇÁ·Î¼¼½º, ±â±â, ¼Ö·ç¼Ç, ´Ü°èº°(-2033³â)
Biologics Safety Testing Market Analysis and Forecast to 2033: Type, Product, Technology, Application, End User, Process, Equipment, Solutions, Stage
»óǰÄÚµå : 1633039
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 378 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,709,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,121,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,534,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

»ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀåÀº 2023³â 43¾ï ´Þ·¯¿¡¼­ 2033³â 105¾ï ´Þ·¯·Î È®´ëµÇ¾úÀ¸¸ç CAGRÀº 9.2%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀåÀº ¾ö°ÝÇÑ ½ÃÇè ÀýÂ÷¸¦ ÅëÇØ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» º¸ÀåÇÏ´Â Àü¹® »ê¾÷À» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ¹«±Õ ½ÃÇè, endotoxin ½ÃÇè, ¼¼Æ÷ÁÖ ÀÎÁõ, ºÎÁ¤ ¿À¿°¹° °ËÃâ µîÀÇ Á¦Ç° ¹× ¼­ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ Áؼö¸¦ ÃËÁøÇÔÀ¸·Î½á »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹é½ÅÀÇ ¾ÈÀüÇÑ °³¹ß°ú »ó¾÷È­¸¦ º¸ÀåÇϰí Á¦¾à ±â¾÷ ¹× »ý¸í °øÇÐ ±â¾÷¿¡ ±â¿©ÇÕ´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀåÀº ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ Áøº¸¿Í ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¼¼Æ÷ ±â¹Ý ºÐ¼® ºÐ¾ß´Â ¹ÙÀÌ¿À ·ÎÁ÷ÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»Çϱ⠶§¹®¿¡ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ¹Ì»ý¹° °Ë»ç´Â ¿À¿° ¹æÁö¿¡ ´ëÇÑ °ü½É Áõ°¡¸¦ ¹Ý¿µÇÏ¿© µÎ ¹øÂ°·Î ³ôÀº ½ÇÀûÀ» ¿Ã¸®°í ÀÖ½À´Ï´Ù. Áö¿ªÀûÀ¸·Î ºÏ¹Ì´Â ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç ¹ÙÀÌ¿À ÀǾàǰ ±â¾÷ÀÇ °­ÇÑ Á¸Àç¿Í ÁÁÀº ±ÔÁ¦ ȯ°æÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. À̾î Á¦¾à»ê¾÷ÀÌ È®¸³µÇ¾î ¾ÈÀü±âÁØÀÌ ¾ö°ÝÇÑ À¯·´ÀÌ À̾îÁý´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶ È®´ë¿Í °Ç°­ °ü¸® ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡·Î ±Þ¼ÓÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Áß±¹°ú Àεµ°¡ ´ë±Ô¸ð Á¦Á¶ ´É·ÂÀ» Ȱ¿ëÇϰí ÀÇ·á ¼öÁØ Çâ»ó¿¡ ÁßÁ¡À» µÎ°í Àֱ⠶§¹®¿¡ ÁÖ¿ä °øÇå±¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀûÁ¦Á¦ÀÇ Ä¡·á ¿ëµµ°¡ °è¼Ó È®´ëµÇ°í ÀÖ´Â °¡¿îµ¥, Á¾ÇÕÀûÀÎ ¾ÈÀü¼º ½ÃÇè ¼Ö·ç¼Ç ¼ö¿ä´Â Áõ°¡ÇÏ°í ½ÃÀå ÁøÃâ±â¾÷¿¡ À¯¸®ÇÑ ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

2023³â ½ÃÀåÀº °­·ÂÇÑ ¼ºÀåÀ» º¸¿´À¸¸ç ½ÃÀå ±Ô¸ð´Â ¾à 9¾ï 5,000¸¸ ºÐ¼®À¸·Î ÃßÁ¤µË´Ï´Ù. ¿£µµÅå½Å °Ë»ç ºÎ¹®ÀÌ 38%ÀÇ Á¡À¯À²À» Â÷ÁöÇÑ ´ÙÀ½ ¹«±Õ °Ë»ç ºÎ¹®ÀÌ 32%, ¸¶ÀÌÄÚÇö󽺸¶ °Ë»ç ºÎ¹®ÀÌ 30%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ºÎ¹®Àº »ý¹°ÇÐÀû Á¦Á¶¿¡¼­ Á¾ÇÕÀûÀÎ ¾ÈÀü¼º Æò°¡¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ¹Ý¿µÇÕ´Ï´Ù. ½ÃÀå È®´ëÀÇ ¹è°æÀº »ý¹°ÇÐÀûÁ¦Á¦ÀÇ ½ÂÀÎ °Ç¼ö Áõ°¡¿Í ¾ö°ÝÇÑ ¾ÈÀü¼º Æò°¡¸¦ ÇÊ¿ä·Î ÇÏ´Â »ý¹°ÇÐÀûÁ¦Á¦ Á¦Á¶ °øÁ¤ÀÇ º¹ÀâÈ­°¡ ÀÖ½À´Ï´Ù.

°æÀï ±¸µµ´Â Âû½º ¸®¹ö ¿¬±¸¼Ò, ·ÐÀÚ ±×·ì, ¸ÓÅ© KGaA¿Í °°Àº ÁÖ¿ä ±â¾÷¿¡ ÀÇÇØ Çü¼ºµÇ¸ç, °¢°¢Àº Àü·«Àû ÆÄÆ®³Ê½Ê°ú ±â¼úÀû Áøº¸¸¦ Ȱ¿ëÇÏ¿© ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ƯÈ÷ FDAÀÇ ¾ö°ÝÇÑ Áöħ°ú »ý¹°ÇÐÀû ¾ÈÀü¿¡ °üÇÑ EU ÁöħÀº ½ÃÀå ¿ªÇп¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¸ÂÃãÇü ÀǷᳪ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ »õ·Î¿î ±âȸ°¡ »ý±â´Â µî ½ÃÀåÀÇ ±Ëµµ´Â À¯¸ÁÇÕ´Ï´Ù. ±×·¯³ª ±ÔÁ¦¿¡ ´ëÇÑ ´ëÀÀ°ú ¾ÈÀü¼º ½ÃÇèÀÇ ºñ¿ë »ó½Â°ú °°Àº °úÁ¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀåÀº ºÏ¹Ì°¡ Áö¹èÀûÀÔ´Ï´Ù. ¹Ì±¹Àº °í±Þ ÀÇ·á ÀÎÇÁ¶ó¿¡ °ßÀεǾî Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ °­·ÂÇÑ ±ÔÁ¦ üÁ¦´Â ½ÃÀå ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù. Áö¼ÓÀûÀÎ ¿¬±¸°³¹ßÀÌ ÁÖµµÀû ÁöÀ§¸¦ ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

À¯·´Àº µÎ ¹øÂ° ½ÃÀåÀÔ´Ï´Ù. µ¶Àϰú ¿µ±¹ µîÀÇ ±¹°¡µéÀÌ °ßÁ¶ÇÑ Á¦¾à»ê¾÷À» ÅëÇØ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ¾ö°ÝÇÑ ¾ÈÀü ±ÔÁ¤ÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¤Àº »ý¹°ÇÐÀû ¾ÈÀü¼º ½ÃÇè¿¡¼­ ³ôÀº ¼öÁØÀ» º¸ÀåÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Áß±¹°ú Àεµ¿¡¼­ ±Þ¼ÓÇÑ °Ç°­ °ü¸® ºÐ¾ßÀÇ °³¹ßÀÌ ÁÖ¿ä ÃßÁø·ÂÀ̵ǰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í »ý¸í°øÇп¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ È¯ÀÚ Àα¸ Áõ°¡µµ ±â¿©ÇÕ´Ï´Ù.

¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«Àº ½ÅÈï ½ÃÀåÀÔ´Ï´Ù. ºê¶óÁú°ú ³²¾ÆÇÁ¸®Ä«´Â ÇöÀúÇÑ ÁøÀüÀ» º¸À̰í ÀÖ½À´Ï´Ù. °Ç°­ °ü¸® ÅõÀÚ Áõ°¡¿Í ÀÎÇÁ¶ó Á¤ºñ°¡ ½ÃÀå ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù. ±×·¯³ª ±ÔÁ¦¿Í °æÁ¦Àû Á¦¾àÀ¸·Î ÀÎÇÑ °úÁ¦µµ ³²¾Æ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ Áß¿ä ÀλçÀÌÆ®

Á¦4Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå Àü¸Á

Á¦5Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå Àü·«

Á¦6Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå ±Ô¸ð

Á¦7Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå ±Ô¸ð : À¯Çüº°

Á¦8Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : Á¦Ç°º°

Á¦9Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : ±â¼úº°

Á¦10Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : ¿ëµµº°

Á¦11Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦12Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : ÇÁ·Î¼¼½ºº°

Á¦13Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : ÀåÄ¡º°

Á¦14Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : ¼Ö·ç¼Çº°

Á¦15Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : ½ºÅ×ÀÌÁöº°

Á¦16Àå »ý¹°ÇÐÀû Á¦Á¦ ¾ÈÀü¼º ½ÃÇè ½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Biologics Safety Testing Market is anticipated to expand from $4.3 billion in 2023 to $10.5 billion by 2033, with a CAGR of 9.2%.

The Biologics Safety Testing Market encompasses the industry dedicated to ensuring the safety and efficacy of biologics through rigorous testing procedures. This market includes products and services such as sterility testing, endotoxin testing, cell line authentication, and adventitious agent detection. It serves pharmaceutical and biotechnology companies by facilitating compliance with stringent regulatory standards, thus ensuring the safe development and commercialization of biologic therapies and vaccines.

The Biologics Safety Testing Market is witnessing robust growth, propelled by advancements in biotechnology and increasing regulatory scrutiny. The cell-based assays segment leads the market, driven by their critical role in ensuring the safety and efficacy of biologics. Microbial testing emerges as the second-highest performing sub-segment, reflecting the heightened focus on contamination control. Geographically, North America dominates the market, benefiting from a strong presence of biopharmaceutical companies and a favorable regulatory environment. Europe follows, with its well-established pharmaceutical industry and stringent safety standards. The Asia-Pacific region is experiencing rapid growth, fueled by expanding biopharmaceutical manufacturing and increased investments in healthcare infrastructure. Within Asia-Pacific, China and India are key contributors, leveraging their large-scale manufacturing capabilities and growing emphasis on improving healthcare standards. As biologics continue to expand their therapeutic applications, the demand for comprehensive safety testing solutions is set to rise, presenting lucrative opportunities for market participants.

In 2023, the market exhibited robust growth, with a market volume estimated at approximately 950 million assays. The endotoxin test segment dominates the market, capturing a substantial 38% share, followed by the sterility test segment at 32%, and the mycoplasma test segment at 30%. This segmentation reflects the heightened demand for comprehensive safety evaluations in biologics production. The market's expansion is driven by increasing biologics approvals and the growing complexities of biologics manufacturing processes, necessitating rigorous safety assessments.

The competitive landscape is shaped by key players such as Charles River Laboratories, Lonza Group, and Merck KGaA, each leveraging strategic partnerships and technological advancements to enhance their market presence. Regulatory frameworks, particularly the FDA's stringent guidelines and the EU's directives on biologics safety, significantly influence market dynamics. The market's trajectory is promising, with emerging opportunities in personalized medicine and biosimilars. However, challenges such as regulatory compliance and high costs of safety testing remain pertinent.

North America dominates the biologics safety testing market. The United States is a major contributor, driven by advanced healthcare infrastructure. The region's strong regulatory framework supports market growth. Continuous research and development further enhance its leading position.

Europe is the second-largest market. Countries like Germany and the United Kingdom drive growth through robust pharmaceutical industries. The region benefits from stringent safety regulations. These regulations ensure high standards in biologics safety testing.

Asia Pacific shows significant potential. Rapidly developing healthcare sectors in China and India are key drivers. Government initiatives and rising investments in biotechnology boost market expansion. The region's growing patient population also contributes.

Latin America and the Middle East and Africa regions have emerging markets. Brazil and South Africa show notable progress. Increasing healthcare investments and improving infrastructure support market growth. However, challenges remain due to regulatory and economic constraints.

Key Companies

Charles River Laboratories, Bio Reliance, SGS Life Sciences, Wu Xi App Tec, Eurofins Scientific, Sartorius Stedim Biotech, Lonza Group, Thermo Fisher Scientific, Merck KGa A, Pace Analytical Services, Toxikon, Cygnus Technologies, Viva Biotech, Creative Bioarray, Gen Script, Abzena, Selexis, Pro Bio Gen, Wu Xi Biologics, Samsung Biologics

Sources

U.S. Food and Drug Administration - Center for Biologics Evaluation and Research, European Medicines Agency, World Health Organization, International Society for Pharmaceutical Engineering, Biotechnology Innovation Organization, National Institutes of Health, U.S. Pharmacopeia, International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Medicines and Healthcare Products Regulatory Agency, International Federation of Pharmaceutical Manufacturers & Associations, American Association of Pharmaceutical Scientists, Parenteral Drug Association, BioProcess International Conference & Exhibition, Annual Meeting of the American Society for Cell Biology, European Congress of Biotechnology, International Pharmaceutical Federation, World Vaccine Congress, Society for Biological Engineering, International Society for Cell and Gene Therapy, International Conference on Biologics and Biosimilars

Research Scope

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Biologics Safety Testing Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Biologics Safety Testing Market Outlook

5: Biologics Safety Testing Market Strategy

6: Biologics Safety Testing Market Size

7: Biologics Safety Testing Market, by Type

8: Biologics Safety Testing Market, by Product

9: Biologics Safety Testing Market, by Technology

10: Biologics Safety Testing Market, by Application

11: Biologics Safety Testing Market, by End User

12: Biologics Safety Testing Market, by Process

13: Biologics Safety Testing Market, by Equipment

14: Biologics Safety Testing Market, by Solutions

15: Biologics Safety Testing Market, by Stage

16: Biologics Safety Testing Market, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â